Posted on April 18th, 2012, 4:00 am
Pharmaceutical Business Review The GSK gains exclusive access to FivePrime's drug discovery platforms in up to six programs to identify first-in-class agents and new mechanisms relevant to refractory asthma and chronic obstructive pulmonary disease (COPD). As per the agreement, ... |